Dr. Tania Dempsey, MD, ABIHM is a world-renowned expert in complex, multisystem diseases such as Mast Cell Activation Syndrome (MCAS) and is sought after internationally for her knowledge of chronic immune dysregulation. She is the founder of the AIM Center of Personalized Medicine, in Purchase, NY, a destination medical center for patients from all over the United States and Internationally. Dr. Dempsey uses functional and integrative medicine to get to the patient’s root cause(s) of illness, to understand why patients get sick, to help them understand their body and why it fails them when it does. Dr. Dempsey’s extensive knowledge and experience with MCAS, Mold, and Lyme and other Vector-Borne Diseases, has propelled her to the forefront of the medical community as a recognized and trusted speaker, researcher, advocate, and physician.
Dr. Dempsey is Board-Certified in Internal Medicine and Integrative and Holistic Medicine. She received her MD degree from The Johns Hopkins University School of Medicine and her BS degree from Cornell University. She completed her Internal Medicine Residency at New York University Medical Center.
She is a founding member and Treasurer of the newly established nonprofit, ISMCAS, International Society for Mast Cell Activation Syndromes. She also serves as Secretary on the Board of Directors of ILADS (International Lyme and Associated Diseases Society) and is Chair of Medical Education Committee. She is a member of the U.S. ME/CFS Clinician Coalition, the American Academy of Ozonotherapy, and ISSWSH (International Society for the Study of Women’s Sexual Health).
She is an accomplished international speaker, writer and thought leader. She is well published in the medical literature on topics related the MCAS and was a co-author of a chapter titled “Urogynecology and Hypermobility” in the 2020 book, Disjointed Navigating the Diagnosis and Management of hypermobile Ehlers-Danlos Syndrome and Hypermobility Spectrum Disorders. She was involved in a research study in collaboration with the TILT team at University of Texas Health Science Center at San Antonio which led to two publications: Mast cell activation may explain many cases of chemical intolerance (2021) and Chemical Intolerance and Mast Cell Activation: A Suspicious Synchronicity (2023). She is also a co-author on the groundbreaking paper, Diagnosis of mast cell activation syndrome: a global “consensus-2”. Her most recent paper from October 2025, Utility of glucagon-like-peptide-1-receptor agonists in mast cell activation syndrome, has been widely referenced in the medical literature and by other experts.
As a trusted expert, Dr. Dempsey is committed to furthering her knowledge of the most innovative, leading edge medical diagnostics and therapeutics and educating patients, their families and other physicians who are searching for answers. Her latest endeavor is cohosting the podcast, Mast Cell Matters, where each episode takes a deep dive with the goal of helping doctors and patients better manage MCAS and its associated co-morbidities.
Dr. Dempsey strives to embody the principles she teaches. Her pursuit of knowledge extends into the science of longevity, immune resilience, and performance optimization. She is passionate about strength training and other lifestyle strategies that optimize metabolic health and build resilience, reflecting her belief that the best medicine is rooted in science and practiced with intention.
